Hemosiderosis in a dialysis patient: treatment with hemofiltration and deferoxamine chelation therapy.
Although the highly permeable membranes utilized in hemofiltration are theoretically more permeable to deferoxamine-chelated iron than the standard cuprophan membranes used in conventional hemodialysis, no clinical data support this contention. Ours are the first published results of a preliminary short-term trial of combined therapy with deferoxamine and hemofiltration in a dialysis patient with hemosiderosis. An average of 15.3 mg of iron was mobilized with a 19.5-liter exchange over only 4 1/2 hours of postdilution hemofiltration. This compares favorable with previous reports in which 8 to 12 hours of dialysis were performed with Kiil dialyzers, and also with the 24-hour urinary excretion of chelated iron in iron-overloaded patients with normal renal function. We conclude that combined therapy with deferoxamine and hemofiltration offers promises as an effective means of iron mobilization in dialysis patients with hemosiderosis.
D000368:Aged; D001769:Blood; D003676:Deferoxamine / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006486:Hemosiderosis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D009400:Nephrosclerosis / Q000150:complications / Q000628:therapy; D006435:Renal Dialysis; D014462:Ultrafiltration / Q000379:methods*
D004338:Drug Combinations; D003676:Deferoxamine